Loading
Chemotherapy-related Skin Toxicity / Colorectal Cancer Treatments and Studies · Review
Healthcare · August 12, 2026
A consensus or society position rather than new primary data.
This narrative systematic review of 17 studies published 2015–2025 synthesizes evidence on treatment-related dermatologic toxicities in cancer patients and their management. The review identifies that dermatologic toxicities are frequent and impose substantial patient burden, supportive care shows potential benefits in some studies, but evidence for pharmaceutical and multidisciplinary interventions remains limited and insufficient to support firm conclusions or standardized recommendations.
Narrative systematic review following PRISMA 2020 guidelines. Studies of cancer patients experiencing dermatologic toxicities from anticancer therapies. Intervention: Pharmaceutical and multidisciplinary care strategies for management of treatment-related dermatologic toxicities. Compared with: Supportive dermatologic care approaches.
Dermatologic toxicities were frequently reported during cancer treatment and generally mild to moderate in severity Supportive dermatologic care strategies were associated with reduced symptom severity and improved quality of life in some studies Evidence for pharmaceutical care and multidisciplinary management was more limited, and available data do not allow firm conclusions regarding their effectiveness
Certainty of evidence explicitly stated as limited, particularly for pharmaceutical care interventions Dermatologic toxicities were frequently reported during cancer treatment and generally mild to moderate in severity
Clinicians should recognize that dermatologic toxicities are common and substantially impact patient quality of life and adherence. While supportive dermatologic care shows promise in some studies, the evidence base for pharmaceutical and multidisciplinary interventions remains insufficient; further high-quality trials are needed to establish standardized management recommendations.
A narrative systematic review synthesizing evidence on incidence, severity, and management of treatment-related dermatologic toxicities, identifying gaps and calling for standardized recommendations rather than reporting a single definitive clinical trial result.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should recognize that dermatologic toxicities are common and substantially impact patient quality of life and adherence. While supportive dermatologic care shows promise in some studies, the evidence base for pharmaceutical and multidisciplinary interventions remains insufficient; further high-quality trials are needed to establish standardized management recommendations.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Background/Objectives: Dermatologic toxicities are among the most common adverse effects of anticancer therapies, including chemotherapy, targeted therapies, and immunotherapies. Although typically non-life-threatening, these conditions can significantly impair quality of life, alter body image, and lead to treatment non-adherence which may compromise health outcomes. This systematic review aims to synthesize the evidence on the incidence, severity, and management of treatment-related dermatologic toxicities, with a focus on pharmaceutical and multidisciplinary care strategies. Methods: This review followed the PRISMA 2020 guidelines. PubMed, ScienceDirect, and Cochrane were searched for studies published between 1 January 2015 and 31 December 2025. Eligibility criteria were defined using the PICO (R) framework. Study selection, data extraction, and risk-of-bias assessment were performed independently by two reviewers. Given study heterogeneity, a narrative synthesis was conducted. Results: Seventeen studies were included. Dermatologic toxicities were frequently reported during cancer treatment and were generally mild to moderate in severity, although they imposed a substantial burden on patients. Supportive dermatologic care strategies were associated with reduced symptom severity and improved quality of life in some studies. Evidence for pharmaceutical care and multidisciplinary management was more limited, and the available data do not allow firm conclusions regarding their effectiveness. Conclusions: Dermatologic toxicities remain an important challenge in oncological care. The evidence suggests potential benefits of supportive care approaches, but the certainty of the evidence is limited, particularly for pharmaceutical care. Further high-quality studies are needed to clarify the impact of these interventions and support standardized recommendations.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.